

# Paola Secchiero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9145008/publications.pdf>

Version: 2024-02-01

277  
papers

11,378  
citations

34105

52  
h-index

40979

93  
g-index

284  
all docs

284  
docs citations

284  
times ranked

13802  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids. <i>Molecules</i> , 2022, 27, 471.	3.8	11
2	Role of vitamin D in the pathogenesis of atheromatosis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 344-353.	2.6	4
3	Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 352, 577473.	2.3	3
4	GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature. <i>Diagnostics</i> , 2021, 11, 604.	2.6	12
5	SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient. <i>Clinical Microbiology and Infection</i> , 2021, 27, 936-937.	6.0	20
6	Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors. <i>Current Oncology</i> , 2021, 28, 2439-2451.	2.2	2
7	Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9449.	4.1	16
8	Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation. <i>Biomolecules</i> , 2021, 11, 1438.	4.0	1
9	The Italian law on body donation: A position paper of the Italian College of Anatomists. <i>Annals of Anatomy</i> , 2021, 238, 151761.	1.9	13
10	Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptive Immunity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11241.	4.1	14
11	Anticancer Activity of Aqueous Extracts from <i>Asparagus officinalis</i> L. Byproduct on Breast Cancer Cells. <i>Molecules</i> , 2021, 26, 6369.	3.8	11
12	TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake. <i>Cell Death and Disease</i> , 2021, 12, 1089.	6.3	4
13	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 778461.	2.8	4
14	Rehabilitation Improves Mitochondrial Energetics in Progressive Multiple Sclerosis: The Significant Role of Robot-Assisted Gait Training and of the Personalized Intensity. <i>Diagnostics</i> , 2020, 10, 834.	2.6	12
15	Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102319.	2.0	7
16	Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFR $\alpha$ /SDH/RAS-P WT GIST. <i>Scientific Reports</i> , 2020, 10, 19829.	3.3	10
17	Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 1156.	3.5	16
18	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. <i>Cancers</i> , 2020, 12, 2126.	3.7	44

#	ARTICLE	IF	CITATIONS
19	COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3474.	4.1	290
20	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR $\alpha$ /SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020, 10, 504.	2.8	16
21	Eosinophils and Purinergic Signaling in Health and Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1339.	4.8	11
22	Sex/Gender-Specific Imbalance in CVD: Could Physical Activity Help to Improve Clinical Outcome Targeting CVD Molecular Mechanisms in Women?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1477.	4.1	24
23	CCR4+ Skin-Tropic Phenotype as a Feature of Central Memory CD8+ T Cells in Healthy Subjects and Psoriasis Patients. <i>Frontiers in Immunology</i> , 2020, 11, 529.	4.8	26
24	Colorectal Cancer Study with Nanostructured Sensors: Tumor Marker Screening of Patient Biopsies. <i>Nanomaterials</i> , 2020, 10, 606.	4.1	10
25	TRAIL treatment prevents renal morphological changes and TGF- $\beta$ <sup>2</sup> -induced mesenchymal transition associated with diabetic nephropathy. <i>Clinical Science</i> , 2020, 134, 2337-2352.	4.3	9
26	Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis. <i>Scientific Reports</i> , 2019, 9, 10870.	3.3	48
27	Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS). <i>Genes</i> , 2019, 10, 634.	2.4	10
28	TRAIL, OPC, and TWEAK in kidney disease: biomarkers or therapeutic targets?. <i>Clinical Science</i> , 2019, 133, 1145-1166.	4.3	30
29	Actively targeted nanocarriers for drug delivery to cancer cells. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 481-496.	5.0	52
30	A novel endovenous scaffold for the treatment of chronic venous obstruction in a porcine model: Histological and ultrastructural assessment. <i>Phlebology</i> , 2019, 34, 336-346.	1.2	1
31	Plasma levels of soluble NCAM in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019, 396, 36-41.	0.6	13
32	TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse. <i>Clinical Science</i> , 2018, 132, 69-83.	4.3	16
33	HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts. <i>Scientific Reports</i> , 2018, 8, 17665.	3.3	50
34	Upregulation of the alternative splicing factor NOVA2 in colorectal cancer vasculature. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6049-6056.	2.0	23
35	Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0203716.	2.5	14
36	TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress. <i>Mediators of Inflammation</i> , 2018, 2018, 1-8.	3.0	8

#	ARTICLE	IF	CITATIONS
37	Novel Compliant Scaffold with Specific Design for Venous System: Results of a Porcine Model Study. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	3
38	T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. <i>Frontiers in Immunology</i> , 2018, 9, 1390.	4.8	70
39	Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2018, 9, 245.	2.4	23
40	Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity. <i>Frontiers in Physiology</i> , 2018, 9, 1000.	2.8	11
41	Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. <i>PLoS ONE</i> , 2018, 13, e0193867.	2.5	40
42	ABO419â€¦Frequency of disease flare and study of the cd4+cd25+highcd127low/- cell populations after discontinuation of anti-tnff therapy in patients with rheumatoid arthritis in persistent remission. , 2018, , .		1
43	The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressive Multiple sclerosis patients (RAGTIME): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 88.	1.6	18
44	Contextâ€¦dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress. <i>BioFactors</i> , 2017, 43, 475-485.	5.4	26
45	The calendar of cytokines: Seasonal variation of circulating cytokines in chronic venous insufficiency. <i>JRSM Cardiovascular Disease</i> , 2017, 6, 204800401772927.	0.7	9
46	Expeditious Synthesis and Biological Characterization of Enantioâ€¦Enriched (â€¦)â€¦Nutlinâ€¦. <i>ChemistrySelect</i> , 2017, 2, 8504-8508.	1.5	2
47	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. <i>Oncogene</i> , 2017, 36, 6617-6626.	5.9	22
48	Association between thyroid hormones and TRAIL. <i>Clinical Biochemistry</i> , 2017, 50, 972-976.	1.9	2
49	Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women. <i>Mediators of Inflammation</i> , 2017, 2017, 1-8.	3.0	6
50	MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 133.	17.0	213
51	The ð³-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. <i>Oncotarget</i> , 2017, 8, 59235-59245.	1.8	19
52	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 70623-70638.	1.8	21
53	Multimodal near-infrared-emitting Plus Silica nanoparticles with fluorescent, photoacoustic, and photothermal capabilities. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4865-4874.	6.7	23
54	Clinical perspectives of TRAIL: insights into central nervous system disorders. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 2017-2027.	5.4	36

#	ARTICLE	IF	CITATIONS
55	Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors—implications for therapeutic potential. <i>Tumor Biology</i> , 2016, 37, 11909-11916.	1.8	3
56	Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 81, 364-374.	2.8	34
57	Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 273-280.	1.5	11
58	Oscillatory flow suppression improves inflammation in chronic venous disease. <i>Journal of Surgical Research</i> , 2016, 205, 238-245.	1.6	18
59	Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells. <i>Journal of Cellular Physiology</i> , 2016, 231, 2700-2710.	4.1	20
60	Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 147-156.	6.4	22
61	Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. <i>Oncotarget</i> , 2016, 7, 18965-18977.	1.8	25
62	Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy. <i>Mediators of Inflammation</i> , 2015, 2015, 1-7.	3.0	2
63	TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	5
64	TRAIL Modulates the Immune System and Protects against the Development of Diabetes. <i>Journal of Immunology Research</i> , 2015, 2015, 1-12.	2.2	35
65	Ultrastructure of internal jugular vein defective valves. <i>Phlebology</i> , 2015, 30, 644-647.	1.2	22
66	Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1837-1849.	5.0	44
67	MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8650-8655.	7.1	86
68	A set of NF- $\kappa$ B-regulated microRNAs induces acquired TRAIL resistance in Lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3355-64.	7.1	68
69	Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus. <i>Acta Diabetologica</i> , 2015, 52, 1003-1006.	2.5	7
70	The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. <i>Oncotarget</i> , 2015, 6, 2385-2396.	1.8	16
71	Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. <i>Reproduction</i> , 2014, 148, 191-198.	2.6	7
72	In Vitro Endothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	3.0	12

#	ARTICLE	IF	CITATIONS
73	Association of Serum Tumor Necrosis Factor-Related Apoptosis Inducing Ligand with Body Fat Distribution as Assessed by Dual X-Rays Absorptiometry. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	3.0	1
74	Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1906-1908.	1.8	0
75	Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model. <i>PLoS ONE</i> , 2014, 9, e115387.	2.5	15
76	Selective induction of TP53/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3. <i>Molecular Carcinogenesis</i> , 2014, 53, 498-504.	2.7	11
77	Modulation of Circulating Cytokine-Chemokine Profile in Patients Affected by Chronic Venous Insufficiency Undergoing Surgical Hemodynamic Correction. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	2.2	24
78	The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. <i>Acta Diabetologica</i> , 2014, 51, 239-246.	2.5	25
79	Inverse Correlation Between Circulating Levels of TNF-Related Apoptosis-Inducing Ligand and 17 $\beta$ -Estradiol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E659-E664.	3.6	14
80	Multiple dye-doped NIR-emitting silica nanoparticles for both flow cytometry and in vivo imaging. <i>RSC Advances</i> , 2014, 4, 18278-18285.	3.6	18
81	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. <i>Molecular and Cellular Endocrinology</i> , 2014, 394, 13-20.	3.2	48
82	Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. <i>Oncotarget</i> , 2014, 5, 4347-4360.	1.8	22
83	The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. <i>Oncotarget</i> , 2014, 5, 12635-12645.	1.8	9
84	Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells. <i>Clinics</i> , 2014, 69, 68-74.	1.5	6
85	Human Colostrum and Breast Milk Contain High Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL). <i>Journal of Human Lactation</i> , 2013, 29, 23-25.	1.6	10
86	Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis. <i>Nanoscale</i> , 2013, 5, 7897.	5.6	47
87	The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. <i>Acta Diabetologica</i> , 2013, 50, 899-906.	2.5	20
88	C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1-Dependent Pathway. <i>Clinical Cancer Research</i> , 2013, 19, 1949-1959.	7.0	36
89	Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. <i>Clinical Nutrition</i> , 2013, 32, 259-264.	5.0	24
90	Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1. <i>Investigational New Drugs</i> , 2013, 31, 780-786.	2.6	2

#	ARTICLE	IF	CITATIONS
91	The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns. <i>Cytokine</i> , 2013, 64, 51-53.	3.2	2
92	Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease. <i>Cytokine</i> , 2013, 63, 92-96.	3.2	24
93	Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells. <i>Nutrition</i> , 2013, 29, 332-337.	2.4	10
94	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	17.0	14
95	GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	3.0	11
96	Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Show a Long-term Stability in the Breast Milk of Mothers of Preterm Infants. <i>Journal of Human Lactation</i> , 2013, 29, 350-353.	1.6	7
97	Inhibitory Effect of Natural Anti-Inflammatory Compounds on Cytokines Released by Chronic Venous Disease Patient-Derived Endothelial Cells. <i>Mediators of Inflammation</i> , 2013, 2013, 1-13.	3.0	18
98	Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts. <i>Clinical Cancer Research</i> , 2013, 19, 3871-3880.	7.0	30
99	Association of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Central Adiposity and Low-Density Lipoprotein Cholesterol. <i>PLoS ONE</i> , 2013, 8, e58225.	2.5	21
100	MiR-34a/c-Dependent PDGFR- $\beta$ Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67581.	2.5	103
101	In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome. <i>PLoS ONE</i> , 2013, 8, e56377.	2.5	29
102	MDM2 Non-Genotoxic Inhibitors as Innovative Therapeutic Approaches for the Treatment of Pediatric Malignancies. <i>Current Medicinal Chemistry</i> , 2013, 20, 2226-2236.	2.4	4
103	Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53 <sup>wildtype</sup> ; JMV-2 But Not Towards p53 <sup>mutated</sup> ; BJAB Leukemic Cells. <i>Current Medicinal Chemistry</i> , 2013, 20, 2712-2722.	2.4	12
104	State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies. <i>Current Medicinal Chemistry</i> , 2012, 19, 4875-4884.	2.4	13
105	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. <i>Current Drug Targets</i> , 2012, 13, 1089-1095.	2.1	8
106	Cell-Based Therapies for Diabetic Complications. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-10.	3.8	39
107	TRAIL, a New Weapon against Neointimal Hyperplasia. <i>Cardiology</i> , 2012, 123, 94-96.	1.4	5
108	Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. <i>Human Reproduction</i> , 2012, 27, 2941-2947.	0.9	30

#	ARTICLE	IF	CITATIONS
109	State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 207-217.	1.6	31
110	Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus. Current Pharmaceutical Design, 2012, 18, 5759-5765.	1.9	10
111	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica, 2012, 97, 1722-1730.	3.5	44
112	The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. Clinical Nutrition, 2012, 31, 1018-1021.	5.0	11
113	Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. Journal of Clinical Virology, 2012, 55, 367-369.	3.1	14
114	TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyl dipeptide or lipopolysaccharide. Cytokine, 2012, 60, 43-46.	3.2	12
115	Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: Potential role of C-reactive protein. Cytokine, 2012, 60, 593-595.	3.2	1
116	JCV+ Patients with Inflammatory Bowel Disease show elevated plasma levels of MIG and SCF. Inflammatory Bowel Diseases, 2012, 18, 1194-1196.	1.9	5
117	TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clinical Science, 2012, 123, 547-555.	4.3	44
118	TRAIL shows potential cardioprotective activity. Investigational New Drugs, 2012, 30, 1257-1260.	2.6	31
119	Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Investigational New Drugs, 2012, 30, 1731-1735.	2.6	6
120	The early determination of circulating TRAIL levels does not predict the development of pre-eclampsia. Placenta, 2012, 33, 135-136.	1.5	7
121	MCL-1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor sorafenib with respect to Dasatinib. British Journal of Haematology, 2012, 157, 510-514.	2.5	7
122	Activation of the p53 pathway induces $\alpha$ -smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. Journal of Cellular Physiology, 2012, 227, 1829-1837.	4.1	12
123	In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Investigational New Drugs, 2012, 30, 405-407.	2.6	3
124	Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Investigational New Drugs, 2012, 30, 803-807.	2.6	4
125	Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells. Investigational New Drugs, 2012, 30, 417-422.	2.6	5
126	The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Investigational New Drugs, 2012, 30, 810-818.	2.6	1

#	ARTICLE	IF	CITATIONS
127	Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. <i>Investigational New Drugs</i> , 2012, 30, 828-832.	2.6	3
128	Endothelial Cells Obtained from Patients Affected by Chronic Venous Disease Exhibit a Pro-Inflammatory Phenotype. <i>PLoS ONE</i> , 2012, 7, e39543.	2.5	42
129	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. <i>Current Drug Targets</i> , 2012, 13, 1215-1221.	2.1	13
130	Merkel-Cell Polyomavirus Is Rarely Associated to B-Chronic Lymphocytic Leukemia and Occurs Late in the Natural History of the Disease. <i>Blood</i> , 2012, 120, 4578-4578.	1.4	0
131	Molecular targets for selective killing of TRAIL-resistant leukemic cells. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 931-942.	3.4	5
132	Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. <i>Molecular and Cellular Endocrinology</i> , 2011, 331, 136-142.	3.2	34
133	Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. <i>Atherosclerosis</i> , 2011, 215, 452-458.	0.8	90
134	Osteoprotegerin promotes vascular fibrosis via a TGF- $\beta$ 1 autocrine loop. <i>Atherosclerosis</i> , 2011, 218, 61-68.	0.8	51
135	TNFRSF11B (tumor necrosis factor receptor superfamily, member 11b). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , .	0.1	0
136	Circulating TRAIL Shows a Significant Post-Partum Decline Associated to Stressful Conditions. <i>PLoS ONE</i> , 2011, 6, e27011.	2.5	6
137	Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjunctival sac fluid of patients with diabetes affected by proliferative retinopathy. <i>Diabetic Medicine</i> , 2011, 28, 1277-1278.	2.3	6
138	Trail downregulates the release of osteoprotegerin (OPG) by primary stromal cells. <i>Journal of Cellular Physiology</i> , 2011, 226, 2279-2286.	4.1	12
139	Recent Advances in the Therapeutic Perspectives of Nutlin-3. <i>Current Pharmaceutical Design</i> , 2011, 17, 569-577.	1.9	150
140	Nutlin-3 Downregulates the Expression of the Oncogene <i>TCL1</i> in Primary B Chronic Lymphocytic Leukemic Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5649-5655.	7.0	17
141	Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway. <i>Clinical Cancer Research</i> , 2011, 17, 762-770.	7.0	48
142	miR-34a Induces the Downregulation of Both <i>E2F1</i> and <i>B-Myb</i> Oncogenes in Leukemic Cells. <i>Clinical Cancer Research</i> , 2011, 17, 2712-2724.	7.0	69
143	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. <i>Blood</i> , 2010, 116, 945-952.	1.4	200
144	TNF- $\alpha$ modulates the migratory response of mesenchymal stem cells to TRAIL. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 1307-1314.	5.4	19

#	ARTICLE	IF	CITATIONS
145	Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). <i>Journal of Cellular Physiology</i> , 2010, 222, 357-364.	4.1	10
146	Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity. <i>British Journal of Haematology</i> , 2010, 148, 957-961.	2.5	11
147	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 <sup>wild-type</sup> CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	2.5	27
148	The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. <i>Leukemia</i> , 2010, 24, 480-483.	7.2	7
149	Treatment With Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Alleviates the Severity of Streptozotocin-Induced Diabetes. <i>Diabetes</i> , 2010, 59, 1261-1265.	0.6	58
150	The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?. <i>Rheumatology</i> , 2010, 49, 1173-1176.	1.9	9
151	Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1733-1734.	0.9	6
152	Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2010, 37, 1461-1466.	2.0	9
153	The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells. <i>Clinical Cancer Research</i> , 2010, 16, 1824-1833.	7.0	23
154	An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 210, 274-277.	0.8	61
155	Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 211, 333-336.	0.8	30
156	Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. <i>PLoS ONE</i> , 2010, 5, e11140.	2.5	128
157	Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction. <i>PLoS ONE</i> , 2009, 4, e4442.	2.5	82
158	Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementary Table). <i>Current Cancer Drug Targets</i> , 2009, 9, 510-518.	1.6	11
159	Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the anti-tumoral surveillance of the anterior surface of the eye. <i>Journal of Cellular Physiology</i> , 2009, 218, 199-204.	4.1	11
160	Role of full-length osteoprotegerin in tumor cell biology. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 841-851.	5.4	70
161	Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2009, 145, 424-426.	2.5	2
162	TRAIL pathway components and their putative role in granulosa cell apoptosis in the human ovary. <i>Differentiation</i> , 2009, 77, 369-376.	1.9	19

#	ARTICLE	IF	CITATIONS
163	Unsung Hero Robert C. Gallo. <i>Science</i> , 2009, 323, 206-207.	12.6	2
164	Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. <i>Blood</i> , 2009, 113, 4300-4308.	1.4	83
165	Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis). <i>Circulation Journal</i> , 2009, 73, 1973-1982.	1.6	38
166	Selection and Characterization of a Novel Agonistic Human Recombinant Anti-Trail-R2 Minibody with Antileukemic Activity. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 73-83.	2.1	9
167	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.. <i>Blood</i> , 2009, 114, 4374-4374.	1.4	0
168	TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27 <sup>Kip1</sup> accumulation in pre-osteoclast precursors. <i>Journal of Cellular Physiology</i> , 2008, 214, 117-125.	4.1	61
169	Potential involvement of TRAIL in Treg cell-mediated osteoclast suppression: Comment on the article by Zaiss et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 1887-1887.	6.7	0
170	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal Cells. <i>Stem Cells</i> , 2008, 26, 2955-2963.	3.2	56
171	Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1063-1065.	3.6	6
172	MicroRNAs as New Players in the Genomic Galaxy and Disease Puzzles. <i>Clinical and Translational Science</i> , 2008, 1, 50-56.	3.1	4
173	Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. <i>Journal of Leukocyte Biology</i> , 2008, 83, 434-437.	3.3	14
174	Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1196-1197.	0.9	6
175	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. <i>Rheumatology</i> , 2008, 48, 293-298.	1.9	29
176	Letter by Secchiero and Zauli Regarding Article, "Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in LDLr <sup>-/-</sup> Mice". <i>Circulation</i> , 2008, 118, e18; author reply e19.	1.6	5
177	The Puzzling Role of TRAIL in Endothelial Cell Biology. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, e4; author reply e5-6.	2.4	11
178	Role of TRAIL in osteoclastogenesis. <i>Blood</i> , 2008, 111, 5413-5413.	1.4	3
179	Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. <i>Blood</i> , 2008, 111, 1287-1294.	1.4	30
180	The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies. <i>Current Pharmaceutical Design</i> , 2008, 14, 2100-2110.	1.9	85

#	ARTICLE	IF	CITATIONS
181	Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. <i>Current Opinion in Hematology</i> , 2008, 15, 42-48.	2.5	66
182	TRAIL and osteoprotegerin: a role in endothelial physiopathology?. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 135.	3.0	33
183	Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3. <i>Circulation Research</i> , 2007, 100, 61-69.	4.5	124
184	Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells. <i>Current Drug Metabolism</i> , 2007, 8, 395-403.	1.2	69
185	Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. <i>Lupus</i> , 2007, 16, 479-482.	1.6	9
186	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. <i>Blood</i> , 2007, 110, 536-543.	1.4	121
187	The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts. <i>Neoplasia</i> , 2007, 9, 853-861.	5.3	41
188	Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Modulates the Expression of Genes Involved in Apoptosis and Cell Cycle in Human Osteoclasts. <i>Anatomical Record</i> , 2007, 290, 838-845.	1.4	8
189	Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. <i>Journal of Cellular Physiology</i> , 2007, 213, 229-236.	4.1	11
190	MDM2 Antagonist Nutlin-3 Suppresses the Proliferation and Differentiation of Human Pre-Osteoclasts Through a p53-Dependent Pathway. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1621-1630.	2.8	22
191	An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction. <i>American Journal of Pathology</i> , 2006, 169, 2236-2244.	3.8	129
192	TRAIL, caspases and maturation of normal and leukemic myeloid precursors. <i>Leukemia and Lymphoma</i> , 2006, 47, 1459-1468.	1.3	6
193	The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. <i>Cytokine and Growth Factor Reviews</i> , 2006, 17, 245-257.	7.2	120
194	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2006, 107, 4122-4129.	1.4	156
195	Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. <i>Journal of Cellular Physiology</i> , 2006, 206, 647-654.	4.1	35
196	Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2006, 207, 158-164.	4.1	33
197	Systemic Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E-Null Diabetic Mice. <i>Circulation</i> , 2006, 114, 1522-1530.	1.6	147
198	TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. <i>Blood</i> , 2005, 105, 3413-3419.	1.4	98

#	ARTICLE	IF	CITATIONS
199	The long and winding road may be getting shorter. <i>Blood</i> , 2005, 105, 4160-4160.	1.4	0
200	Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. <i>Journal of Cellular Physiology</i> , 2005, 204, 975-982.	4.1	25
201	Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2005, 205, 246-252.	4.1	26
202	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. <i>American Journal of Pathology</i> , 2005, 167, 1599-1607.	3.8	43
203	Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes. <i>American Journal of Pathology</i> , 2005, 166, 557-563.	3.8	89
204	Aberrant Expression of Trail in B Chronic Lymphocytic Leukemia (B-CLL) Cells.. <i>Blood</i> , 2005, 106, 4976-4976.	1.4	0
205	TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies. <i>Current Pharmaceutical Design</i> , 2004, 10, 3673-3681.	1.9	43
206	Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. <i>Blood</i> , 2004, 104, 2418-2424.	1.4	422
207	Sensitization of multidrug resistant human osteosarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. <i>International Journal of Oncology</i> , 2004, 25, 1599.	3.3	8
208	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. <i>Experimental Hematology</i> , 2004, 32, 925-934.	0.4	13
209	TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 1965-1974.	5.4	123
210	Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. <i>Journal of Neurochemistry</i> , 2004, 86, 126-135.	3.9	67
211	Evidence for a Proangiogenic Activity of TNF-Related Apoptosis-Inducing Ligand. <i>Neoplasia</i> , 2004, 6, 364-373.	5.3	55
212	TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. <i>Blood</i> , 2004, 103, 517-522.	1.4	110
213	TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. <i>Blood</i> , 2004, 104, 2044-2050.	1.4	99
214	TRAIL Activates a Caspase 9/7-Dependent Pathway in Caspase 8/10-Defective SK-N-SH Neuroblastoma Cells with Two Functional End Points: Induction of Apoptosis and PGE2 Release. <i>Neoplasia</i> , 2003, 5, 457-466.	5.3	11
215	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sequentially Upregulates Nitric Oxide and Prostanoid Production in Primary Human Endothelial Cells. <i>Circulation Research</i> , 2003, 92, 732-740.	4.5	119
216	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF- $\alpha$ promote the NF- $\kappa$ B-dependent maturation of normal and leukemic myeloid cells. <i>Journal of Leukocyte Biology</i> , 2003, 74, 223-232.	3.3	27

#	ARTICLE	IF	CITATIONS
217	TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways. <i>Circulation</i> , 2003, 107, 2250-2256.	1.6	283
218	IFN- $\gamma$ Increases Interleukin-10 Expression in Primary Activated Human CD8+T Cells. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1167-1173.	1.2	12
219	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7634-7639.	7.1	295
220	Tumor necrosis factor- $\alpha$ -related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. <i>Blood</i> , 2002, 100, 2421-2429.	1.4	83
221	NK-active cytokines IL-2, IL-12, and IL-15 selectively modulate specific protein kinase C (PKC) isoforms in primary human NK cells. <i>The Anatomical Record</i> , 2002, 266, 87-92.	1.8	32
222	TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE(2) production in cells of the myeloid lineage. <i>Journal of Leukocyte Biology</i> , 2002, 72, 986-94.	3.3	14
223	Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor- $\alpha$ -related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. <i>Blood</i> , 2001, 97, 2596-2603.	1.4	93
224	Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor- $\alpha$ -related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. <i>Blood</i> , 2001, 98, 2220-2228.	1.4	69
225	Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor- $\alpha$ -related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4+ T cells. <i>Blood</i> , 2001, 98, 2474-2481.	1.4	31
226	HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway. <i>FASEB Journal</i> , 2001, 15, 483-491.	0.5	37
227	Stromal derived factor-1 alpha (SDF-1 alpha) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway. <i>Journal of Leukocyte Biology</i> , 2001, 69, 263-70.	3.3	37
228	Engagement of CD28 Modulates CXC Chemokine Receptor 4 Surface Expression in Both Resting and CD3-Stimulated CD4+ T Cells. <i>Journal of Immunology</i> , 2000, 164, 4018-4024.	0.8	25
229	Differential effects of stromal derived factor-1 $\alpha$ (SDF-1 $\alpha$ ) on early and late stages of human megakaryocytic development. <i>The Anatomical Record</i> , 2000, 260, 141-147.	1.8	23
230	Infection of CD34+ hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). <i>Blood</i> , 2000, 96, 126-131.	1.4	39
231	Identification and Analysis of a Novel Heparin-Binding Glycoprotein Encoded by Human Herpesvirus 7. <i>Journal of Virology</i> , 2000, 74, 4530-4540.	3.4	24
232	Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14620-14625.	7.1	25
233	IFN- $\gamma$ Reduces IL-2 Production and IL-2 Receptor Function in Primary CD4+T Cells. <i>Journal of Immunology</i> , 2000, 164, 2296-2302.	0.8	36
234	HIV-1 Tat-mediated Inhibition of the Tyrosine Hydroxylase Gene Expression in Dopaminergic Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 4159-4165.	3.4	77

#	ARTICLE	IF	CITATIONS
235	Stromal derived factor-1 $\alpha$ induces apoptosis in activated primary CD4+ T cells. <i>Aids</i> , 2000, 14, 748-750.	2.2	10
236	Infection of CD34+ hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). <i>Blood</i> , 2000, 96, 126-131.	1.4	10
237	Identification and Analysis of a Novel Heparin-Binding Glycoprotein Encoded by Human Herpesvirus 7. <i>Journal of Virology</i> , 2000, 74, 4530-4540.	3.4	2
238	TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. <i>Blood</i> , 2000, 95, 3716-24.	1.4	129
239	Infection of CD34(+) hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). <i>Blood</i> , 2000, 96, 126-31.	1.4	10
240	Development of Recombinant Diagnostic Reagents Based on pp85(U14) and p86(U11) Proteins To Detect the Human Immune Response to Human Herpesvirus 7 Infection. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3980-3985.	3.9	14
241	Human Immunodeficiency Virus Type 1 Nef Protein Sensitizes CD4+ T Lymphoid Cells to Apoptosis via Functional Upregulation of the CD95/CD95 Ligand Pathway. <i>Blood</i> , 1999, 93, 1000-1010.	1.4	45
242	Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. <i>Blood</i> , 1999, 93, 1000-10.	1.4	38
243	Extracellular HIV-1 tat protein up-regulates the expression of surface CXCR4-chemokine receptor 4 in resting CD4+ T cells. <i>Journal of Immunology</i> , 1999, 162, 2427-31.	0.8	85
244	Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. <i>Journal of Immunology</i> , 1999, 163, 3169-75.	0.8	37
245	Enforced expression of human bcl-2 in CD4+ T cells enhances human herpesvirus 7 replication and induction of cytopathic effects. <i>European Journal of Immunology</i> , 1998, 28, 1587-1596.	2.9	5
246	Accumulation of catalytically active PKC- $\eta$ into the nucleus of HL-60 cell line plays a key role in the induction of granulocytic differentiation mediated by all-transretinoic acid. <i>British Journal of Haematology</i> , 1998, 100, 541-549.	2.5	29
247	Human herpesvirus type 7 in Hodgkin's disease. <i>British Journal of Haematology</i> , 1998, 101, 492-499.	2.5	27
248	Progressive and Persistent Downregulation of Surface CXCR4 in CD4+ T Cells Infected With Human Herpesvirus 7. <i>Blood</i> , 1998, 92, 4521-4528.	1.4	28
249	Human Herpesvirus 7 Infection Induces Profound Cell Cycle Perturbations Coupled to Disregulation of cdc2 and Cyclin B and Polyploidization of CD4+ T Cells. <i>Blood</i> , 1998, 92, 1685-1696.	1.4	29
250	Human Herpesvirus 7 Infection Induces Profound Cell Cycle Perturbations Coupled to Disregulation of cdc2 and Cyclin B and Polyploidization of CD4+ T Cells. <i>Blood</i> , 1998, 92, 1685-1696.	1.4	10
251	The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+ Cells. <i>Blood</i> , 1998, 92, 472-480.	1.4	4
252	Progressive and Persistent Downregulation of Surface CXCR4 in CD4+ T Cells Infected With Human Herpesvirus 7. <i>Blood</i> , 1998, 92, 4521-4528.	1.4	6

#	ARTICLE	IF	CITATIONS
253	The induction of megakaryocyte differentiation is accompanied by selective Ser133 phosphorylation of the transcription factor CREB in both HEL cell line and primary CD34+ cells. <i>Blood</i> , 1998, 92, 472-80.	1.4	8
254	Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to dysregulation of cdc2 and cyclin B and polyploidization of CD4(+) T cells. <i>Blood</i> , 1998, 92, 1685-96.	1.4	7
255	Progressive and persistent downregulation of surface CXCR4 in CD4(+) T cells infected with human herpesvirus 7. <i>Blood</i> , 1998, 92, 4521-8.	1.4	3
256	Identification of Envelope Glycoproteins H and B Homologues of Human Herpesvirus 7. <i>Intervirology</i> , 1997, 40, 22-32.	2.8	9
257	Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. <i>Nature Medicine</i> , 1997, 3, 1394-1397.	30.7	411
258	The engagement of CD4 surface antigen in the HEL haemopoietic cell line up-regulates the transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) promoter activity. <i>British Journal of Haematology</i> , 1997, 97, 571-578.	2.5	3
259	Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. <i>Journal of Virology</i> , 1997, 71, 4571-4580.	3.4	80
260	The 85-kilodalton phosphoprotein (pp85) of human herpesvirus 7 is encoded by open reading frame U14 and localizes to a tegument substructure in virion particles. <i>Journal of Virology</i> , 1997, 71, 5758-5763.	3.4	42
261	Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels. <i>Journal of Immunology</i> , 1997, 159, 3412-23.	0.8	20
262	Human Herpesvirus 7 induces CD4(+) T-cell death by two distinct mechanisms: necrotic lysis in productively infected cells and apoptosis in uninfected or nonproductively infected cells. <i>Blood</i> , 1997, 90, 4502-12.	1.4	38
263	Latent BK virus infection and Kaposi's sarcoma pathogenesis. , 1996, 66, 717-722.		72
264	Cloning, restriction endonuclease mapping and partial sequence analysis of the genome of human herpesvirus 7 strain JI. <i>Journal of General Virology</i> , 1996, 77, 1901-1912.	2.9	18
265	Human herpesvirus 6 and Epstein-Barr virus in Hodgkin's disease: a controlled study by polymerase chain reaction and in situ hybridization. <i>American Journal of Pathology</i> , 1996, 149, 1501-10.	3.8	36
266	Interference between human herpesvirus 7 and HIV-1 in mononuclear phagocytes. <i>Journal of Immunology</i> , 1996, 156, 2004-8.	0.8	36
267	Detection of Human Herpesvirus 6 in Plasma of Children with Primary Infection and Immunosuppressed Patients by Polymerase Chain Reaction. <i>Journal of Infectious Diseases</i> , 1995, 171, 273-280.	4.0	295
268	Quantitative PCR for human herpesviruses 6 and 7. <i>Journal of Clinical Microbiology</i> , 1995, 33, 2124-2130.	3.9	80
269	Identification of human telomeric repeat motifs at the genome termini of human herpesvirus 7: structural analysis and heterogeneity. <i>Journal of Virology</i> , 1995, 69, 8041-8045.	3.4	47
270	Human Herpesvirus 6: A Survey of Presence and Variant Distribution in Normal Peripheral Lymphocytes and Lymphoproliferative Disorders. <i>Journal of Infectious Diseases</i> , 1994, 170, 211-215.	4.0	121

#	ARTICLE	IF	CITATIONS
271	<i>In Vitro</i> Susceptibility of <i>Macaca nemestrina</i> to Human Herpesvirus 6: A Potential Animal Model of Coinfection with Primate Immunodeficiency Viruses. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 181-187.	1.1	24
272	Biological and Molecular Characteristics of Human Herpesvirus 7: In Vitro Growth Optimization and Development of a Syncytia Inhibition Test. <i>Virology</i> , 1994, 202, 506-512.	2.4	54
273	CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 3872-3876.	7.1	229
274	Human herpesvirus 6 (variant A) in Kaposi's sarcoma. <i>Lancet</i> , The, 1993, 341, 1288-1289.	13.7	63
275	Characterization of Human Herpesvirus 6 Strains Isolated from Patients with Exanthem Subitum with or without Cutaneous Rash. <i>Journal of Infectious Diseases</i> , 1992, 166, 689-689.	4.0	18
276	Presence and physical state of HPV DNA in prostate and urinary-tract tissues. <i>International Journal of Cancer</i> , 1992, 52, 359-365.	5.1	51
277	Is vestibular papillomatosis associated with human papillomavirus?. <i>Journal of Medical Virology</i> , 1991, 35, 7-13.	5.0	13